Molecular Partners Ag Stock Operating Margin

MOLN Stock  USD 3.77  0.10  2.58%   
Molecular Partners AG fundamentals help investors to digest information that contributes to Molecular Partners' financial success or failures. It also enables traders to predict the movement of Molecular Stock. The fundamental analysis module provides a way to measure Molecular Partners' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Molecular Partners stock.
Last ReportedProjected for Next Year
Operating Profit Margin(8.68)(8.25)
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Molecular Partners AG Company Operating Margin Analysis

Molecular Partners' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.

Operating Margin

 = 

Operating Income

Revenue

X

100

More About Operating Margin | All Equity Analysis

Current Molecular Partners Operating Margin

    
  (16.13) %  
Most of Molecular Partners' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Molecular Partners AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Molecular Operating Margin Driver Correlations

Understanding the fundamental principles of building solid financial models for Molecular Partners is extremely important. It helps to project a fair market value of Molecular Stock properly, considering its historical fundamentals such as Operating Margin. Since Molecular Partners' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Molecular Partners' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Molecular Partners' interrelated accounts and indicators.
0.96-0.16-0.49-0.380.15-0.26-0.361.0-0.70.010.720.660.570.670.680.490.63
0.96-0.38-0.48-0.350.02-0.33-0.60.96-0.70.00.740.720.640.750.750.450.65
-0.16-0.380.3-0.130.630.420.86-0.180.00.23-0.13-0.5-0.65-0.53-0.520.13-0.22
-0.49-0.480.3-0.060.390.440.29-0.510.370.36-0.1-0.17-0.46-0.18-0.170.02-0.09
-0.38-0.35-0.13-0.06-0.67-0.060.14-0.340.58-0.65-0.86-0.59-0.39-0.16-0.15-0.91-0.81
0.150.020.630.39-0.670.40.40.12-0.470.570.44-0.03-0.33-0.29-0.290.510.27
-0.26-0.330.420.44-0.060.40.39-0.250.10.19-0.12-0.32-0.32-0.3-0.24-0.18-0.16
-0.36-0.60.860.290.140.40.39-0.370.340.02-0.44-0.58-0.64-0.6-0.58-0.14-0.42
1.00.96-0.18-0.51-0.340.12-0.25-0.37-0.69-0.020.690.650.560.670.680.450.6
-0.7-0.70.00.370.58-0.470.10.34-0.69-0.47-0.68-0.33-0.19-0.1-0.11-0.46-0.42
0.010.00.230.36-0.650.570.190.02-0.02-0.470.440.18-0.1-0.26-0.250.490.3
0.720.74-0.13-0.1-0.860.44-0.12-0.440.69-0.680.440.810.610.580.570.890.94
0.660.72-0.5-0.17-0.59-0.03-0.32-0.580.65-0.330.180.810.890.830.820.70.92
0.570.64-0.65-0.46-0.39-0.33-0.32-0.640.56-0.19-0.10.610.890.790.790.480.77
0.670.75-0.53-0.18-0.16-0.29-0.3-0.60.67-0.1-0.260.580.830.791.00.390.69
0.680.75-0.52-0.17-0.15-0.29-0.24-0.580.68-0.11-0.250.570.820.791.00.370.67
0.490.450.130.02-0.910.51-0.18-0.140.45-0.460.490.890.70.480.390.370.9
0.630.65-0.22-0.09-0.810.27-0.16-0.420.6-0.420.30.940.920.770.690.670.9
Click cells to compare fundamentals
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
Competition

Molecular Pretax Profit Margin

Pretax Profit Margin

(8.37)

At this time, Molecular Partners' Pretax Profit Margin is very stable compared to the past year.
Based on the recorded statements, Molecular Partners AG has an Operating Margin of -16.1318%. This is 54.01% lower than that of the Biotechnology sector and 85.61% lower than that of the Health Care industry. The operating margin for all United States stocks is 192.77% higher than that of the company.

Molecular Operating Margin Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Molecular Partners' direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Molecular Partners could also be used in its relative valuation, which is a method of valuing Molecular Partners by comparing valuation metrics of similar companies.
Molecular Partners is currently under evaluation in operating margin category among related companies.

Molecular Partners Current Valuation Drivers

We derive many important indicators used in calculating different scores of Molecular Partners from analyzing Molecular Partners' financial statements. These drivers represent accounts that assess Molecular Partners' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Molecular Partners' important valuation drivers and their relationship over time.
201920202021202220232024 (projected)
Market Cap407.6M433.1M543.4M196.6M115.2M109.4M
Enterprise Value334.4M306.6M477.6M113.5M(68.1M)(64.7M)

Molecular Fundamentals

About Molecular Partners Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Molecular Partners AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Molecular Partners using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Molecular Partners AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Molecular Partners offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Molecular Partners' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Molecular Partners Ag Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Molecular Partners Ag Stock:

Complementary Tools for Molecular Stock analysis

When running Molecular Partners' price analysis, check to measure Molecular Partners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Molecular Partners is operating at the current time. Most of Molecular Partners' value examination focuses on studying past and present price action to predict the probability of Molecular Partners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Molecular Partners' price. Additionally, you may evaluate how the addition of Molecular Partners to your portfolios can decrease your overall portfolio volatility.
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Money Managers
Screen money managers from public funds and ETFs managed around the world
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Is Molecular Partners' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Molecular Partners. If investors know Molecular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Molecular Partners listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.07)
Revenue Per Share
0.215
Quarterly Revenue Growth
(0.62)
Return On Assets
(0.17)
Return On Equity
(0.30)
The market value of Molecular Partners is measured differently than its book value, which is the value of Molecular that is recorded on the company's balance sheet. Investors also form their own opinion of Molecular Partners' value that differs from its market value or its book value, called intrinsic value, which is Molecular Partners' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Molecular Partners' market value can be influenced by many factors that don't directly affect Molecular Partners' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Molecular Partners' value and its price as these two are different measures arrived at by different means. Investors typically determine if Molecular Partners is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Molecular Partners' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.